WW plans to integrate its weight-loss plans and recipes with telehealth consultations and doctor-approved prescription drugs in a planned $106M acquisition of digital health company Sequence.
Launched in 2021, Sequence has about 24,000 members who pay $99 a month for Services that include telehealth appointments with doctors who can prescribe drugs that mimic the hormone glucagon-like peptide-1 (GLP-1)-which stimulates insulin production and also slows emptying of the stomach.
These drugs include Ozempic, which is prescribed for Type 2 Diabetes but has become extremely popular-leading to pharmacy shortages in some states-because of its ability to help people lose weight.
It's the latest digital evolution for Weight Watchers, which provides customized nutrition plans, lifestyle trackers, 24/7 coach support and more than 12,000 healthy meal recipes via its app.
First-time users of Sequence take a online five minute quiz about their medical and weight-loss history before speaking to a Clinician who then develops a treatment plan.
The acquisition is expected to close in the second quarter of 2023.
SOURCE: Media Post 3/9/23
